He discusses the big year oncology has had, including in the RAS space, and highlights key catalysts he will be watching throughout the remainder of 2026. Coverage brought to you by

Based on his analysis, a higher percentage of biotech companies have been trading up on positive data than the previous year. He also discusses going back to the drawing board on cardiovascular targets, in vivo CAR-T programs, and his key catatalysts to watch throughout the rest of the year. Coverage brought to you by

He discusses M&A, which he believes can continue, and the IPO market that finally opened up in 2026. Plus, how positive headlines like Moderna & Merck's cancer vaccine have been causing investors to look at the sector. Coverage brought to you by

The work could help guide drug discovery and development by revealing how disease disrupts cells.

He says that capital is returning to the sector and that investors have been doing more scientific due diligence recenetly. Plus, the impact of AI on biotech.

Interviewed by MassBio CEO Kendalle Burlin O'Connell, Congressman Auchincloss of Massachusetts describes the impact he believes a tightening of funding for basic research is having on our industry and measures he would take to bolster innovative research. He advocates for making it easier to run early stage clinical trials in the U.S. and for it to be less costly for small biotech companies to engage with FDA. Chapters The economic impact of biotech - 1:28 Global competition

Interviewed by MassBio CEO Kendalle Burlin O'Connell, Ilan Ganot describes co-founding Solid Biosciences in honor of his child with Duchenne muscular dystrophy and Daniel Fischer discusses co-founding Tevard Biosciences in honor of his child with Dravet syndrome. Chapters Intros - 1:11 Ilan Ganot | Starting a DMD company - 6:17 Daniel Fischer | Starting a Dravet company - 8:39 The Massachusetts ecosystem - 10:36 Being a CEO - 18:48 Advice for other parents - 23:43 Incentivizi

MassBio CEO Kendalle Burlin O'Connell highlights key findings of the report, including that employment in life sciences was down in 2025 for the first time in decades, and suggests that we should be both optimistic about the current state of the sector but mindful to make seed investments to keep it up over the longer term. Download the Report

Aofie Regan, Director of Charitable Programmes and Impact at GOSH's Children's Charity, describes the research that happens there, which is transparently on display for the public to see from the street. In addition to do work directly there that might not be driven forward on its own, they also recently initiated a clinical trials funding programme.

He says he sees generalist investors coming back to biotech for the first time in a while, which have been benefitting the IPO market and other areas of the sector. Plus, the areas he is focused on today and what it take to be a successful IPO candidate. Coverage brought to you by

He discusses in vivo CAR-T data from Legend, and how Incyte is planning for the loss of exclusivity on Jakafi. Plus, his take on last week's summit data, and watching out for future catalysts from Ionis and Tyra.

He believes that GLPs will always be the backbone of weight loss therapies and points out that they are the only weight loss medicines that have shown a cardiovascular benefit. Plus, why he thinks entrepreneurs in Europe should take a nod from other areas and be more nimble and take more risks in the future.

He says the mood overall in biotech is dramatically better than it has been during the previous 2-3 years, and he is unsure about whether the AI factor will continue to attract investors like generalists who have been revisiting the sector.

He describes how new technologies will revolutionize biotech, and his hope that more UK companies grow for the long-term rather than being sold to foreign multi-nationals.

Steijn Ribbens describes the facility and how it is built to accelerate oncology research and the biotech sector in France, and how Kadans is working to build out biotech in this way throughout Europe.

Paris Saclay Cancer Cluster President Eric Vivier describes the building, the goal of ramping biotech innovation for oncology in France, and what areas of science will be a focus.

He discusses the importance of this new building and the value it brings by congregating France's innovators together. Plus the elements that Paris Saclay Cancer Cluster looks for when supporting a company. It all starts with great science.

Jacques Volckmann describes the thought that went into creating PSCC, and why he is excited for the opening of THE HIVE, which Sanofi will have a presence in. Plus, what interests him in oncology today.

He comments on the progress of PD-1 x VEGF, a closely watched RET inhibitor, and how the field is doing in head & neck cancer lately. Plus, the presentation that everyone is waiting for in pancreatic cancer.

He shares his take on the ability for mid and small cap biotech companies to raise money and go public, which he describes as being very catalyst dependent.